Drug Combination Details

General Information of the Combination (ID: C42712)
Name Metformin   NP Info  + Gefitinib   Drug Info 
Structure +
Disease
Lung cancer [ICD-11: 2C25]
Clinical trial [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Enhancing Drug Efficacy by This Combination
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [2]
                    Molecule(s)
                    Regulation		 Up-regulation Expression c-RAF  Molecule Info 
Pathway MAP
Up-regulation Expression PRKAA2  Molecule Info 
Pathway MAP
                    In-vitro Model Calu-3 CVCL_0609 Lung adenocarcinoma Homo sapiens
GLC-82 CVCL_3371 Non-small cell lung cancer Homo sapiens
NCI-H1975 CVCL_1511 Lung adenocarcinoma Homo sapiens
NCI-H460 CVCL_0459 Lung large cell carcinoma Homo sapiens
NCI-H1299 CVCL_0060 Lung large cell carcinoma Homo sapiens
A-549 CVCL_0023 Lung adenocarcinoma Homo sapiens
                    Experimental
                    Result(s)		 Metformin and gefitinib are synergistic in LKB1 wild-type NSCLC cells.
References
Reference 1 ClinicalTrials.gov (NCT03071705) Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma.
Reference 2 Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. Clin Cancer Res. 2013 Jul 1;19(13):3508-19.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link